Global Advanced Liver Cancer Market Trends 2025–2029: Regional Outlook and Sizing Analysis
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Advanced Liver Cancer Market In The Coming Years?
The market size for advanced liver cancer has seen a swift expansion in the recent past. It is projected to rise from $1.89 billion in 2024 to $2.16 billion in 2025, yielding a compound annual growth rate (CAGR) of 14.5%. The escalation during the historic period can be linked to heightened awareness about liver cancer, a rising number of patients, an increasing need for targeted therapies, an expanded healthcare infrastructure, and heightened demand for minimally invasive treatments.
Rapid expansion is predicted for the advanced liver cancer market in the coming years, escalating to a value of $3.74 billion in 2029 and showcasing a compound annual growth rate (CAGR) of 14.7%. This growth during the forecast period can be ascribed to factors such as rising occurrence of liver cancer, escalating healthcare expenditure, growing prevalence of genetic conditions, wider embrace of precision medicine, and increased utilization of screening and diagnostic tests. Future trends are set to include the incorporation of AI in treatment processes, breakthroughs in innovative drug and treatment creation, broader scope of research and development initiatives, advancements in specified therapeutics, and an increasing appetite for personalized medicine.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp
Which Growth Drivers Are Shaping The Advanced Liver Cancer Market Outlook?
The consistent increase in long-lasting hepatitis infections is likely to fuel the progression of the advanced liver cancer market. These infections, persisting for over six months, can lead to liver injury, cirrhosis, and liver cancer. Factors such as insufficient screening, lack of immunization, and postponed treatment access contribute to the rise in long-lasting hepatitis infections. Chronic hepatitis B (HBV) or hepatitis C (HCV) infections are the predominant causes of liver cirrhosis and hepatocellular carcinoma (HCC), which is the most typical type of liver cancer. Long-lasting viral infections can cause liver inflammation and damage, eventually leading to cancer. As these infections persist, there is a higher risk for more people to develop advanced liver cancer. For example, in April 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that 254 million people globally were affected by chronic hepatitis B in 2022, with an annual occurrence of 1.2 million new cases. Consequently, the consistent increase in long-lasting hepatitis infections is contributing to the expansion of the advanced liver cancer market.
What Is The Segment Breakdown Of The Advanced Liver Cancer Market?
The advanced liver cancermarket covered in this report is segmented –
1) By Test Type: Imaging Test; Biopsy; Genomic Test; Other Test Types
2) By Technology: Fluorescent In Situ Hybridization; Next Generation Sequencing; Fluoroimmunoassay; Comparative Genomic Hybridization; Immunohistochemical; Other Technologies
3) By Distribution Channel: Direct Tenders; Retail Sales; Other Distribution Channel
4) By Application: Screening; Diagnostic And Predictive; Prognostic; Research
5) By End-User: Hospitals; Cancer Research Centers; Academic Institutes; Diagnostic Centers; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Imaging Test: Ultrasound; CT (Computed Tomography) Scan; MRI (Magnetic Resonance Imaging); PET (Positron Emission Tomography) Scan
2) By Biopsy: Needle Biopsy; Laparoscopic Biopsy; Surgical Biopsy
3) By Genomic Test: Next-Generation Sequencing (NGS); PCR (Polymerase Chain Reaction) Testing; Genetic Mutation Profiling
4) By Other Test Types: Serum Biomarker Testing; Liver Function Tests; Alpha-Fetoprotein (AFP) Test; Elastography Tests
How Are Global Trends Impacting The Development Of The Advanced Liver Cancer Market?
Key players in the sophisticated liver cancer market are concentrated on the creation of novel drugs, such as human monoclonal antibodies. These aim to boost the effectiveness of treatment and reduce adverse side effects, thus enhancing patient success rates. A human monoclonal antibody is a laboratory-crafted molecule designed to replicate the immune system’s role in fighting off harmful pathogens or cancer cells. It targets specific antigens present on these harmful bodies, instigating an immune reaction. An example of this is when AstraZeneca, an American pharmaceutical firm, revealed in October 2022 that the US Food and Drug Administration (FDA) had approved Imjudo (tremelimumab) along with Imfinzi (durvalumab) for treating adults with inoperable hepatocellular carcinoma (HCC) – the most prevalent type of liver cancer. This approval came after the results from the HIMALAYA Phase III study showcased that this combined treatment minimized the death risk by 22% compared to sorafenib, with roughly 31% of patients still alive after three years, in contrast to the 20% survival rate under sorafenib treatment. The STRIDE regimen, comprising a one-time dose of Imjudo and regular doses of Imfinzi every four weeks, presents a fresh treatment alternative for patients with scarce choices.
Who Are The Major Stakeholders Operating In The Advanced Liver Cancer Market?
Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer–global-market-report
Which Region Is Likely To Register The Fastest Growth In The Advanced Liver Cancer Market?
North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=20706&type=smp
Browse Through More Reports Similar to the Global Advanced Liver Cancer Market 2025, By The Business Research Company
Lung Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
Lung Cancer Diagnostic And Screening Global Market Report 2025
Small Cell Lung Cancer Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
